CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 28.88×, higher than 95% of its Biotechnology peers (median 5.64×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.26BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
407.23%vs all stocks
Market Capitalization
2.26BUSDvs all stocks (USD)
Enterprise Value
2.01BUSDvs all stocks (USD)
Forward P/E
-23.06xvs Biotechnology peers
Price to Book (MRQ)
9.69xvs Biotechnology peers
Enterprise to EBITDA
-57.07xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-16.60%vs Biotechnology peers
Return on Equity (TTM)
-34.25%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-49.30MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-29.10MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.60MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-38.60MUSDvs all stocks (USD)
Pre-tax Income
-41.72MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-41.72MUSDFY2025 · Dec 31, 2025EBIT
-35.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-35.28MUSDFY2025 · Dec 31, 2025Research & Development
22.84MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
15.76MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.59MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.82MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.71USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.71USDFY2025 · Dec 31, 2025Basic Shares Outstanding
11.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.72MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-25.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
57.98MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.72MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.49MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.26MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.42MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.42MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.31MSharesUpdated Jul 19, 2026Float Shares
9.58MSharesUpdated Jul 19, 2026Shares Short
2.37MSharesUpdated Jul 19, 2026Short Ratio
6.81daysvs all stocks
Short % of Shares Outstanding
18.67%vs all stocks
% Held by Insiders
11.65%vs all stocks
% Held by Institutions
96.79%vs all stocks
Total Cash (MRQ)
261.85MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
18.26USDUpdated Jul 19, 2026Total Debt (MRQ)
20.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0877xvs Biotechnology peers
Current Ratio (MRQ)
28.88xvs Biotechnology peers
Book Value per Share (MRQ)
16.23USDUpdated Jul 19, 2026Total Assets
59.56MUSDvs all stocks (USD)
Total Current Assets
58.99MUSDFY2025 · Dec 31, 2025Total Liabilities
31.58MUSDFY2025 · Dec 31, 2025Total Non-current Assets
572.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.23MUSDFY2025 · Dec 31, 2025Total Current Liabilities
11.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
57.98MUSDFY2025 · Dec 31, 2025Accounts Receivable
0.00USDFY2025 · Dec 31, 2025Accounts Payable
4.59MUSDFY2025 · Dec 31, 2025Short-term Debt
202.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.90MUSDFY2025 · Dec 31, 2025Long-term Debt
431.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
17.76MUSDFY2025 · Dec 31, 2025Common Stock (Book)
12.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-135.45MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
27.98MUSDvs all stocks (USD)
52-Week Low
29.59USDUpdated Jul 19, 202652-Week High
161.38USDUpdated Jul 19, 202652-Week Change
407.23%vs all stocks
50-Day MA
125.08USDUpdated Jul 19, 2026200-Day MA
105.88USDUpdated Jul 19, 2026Avg 10-Day Volume
213.20KSharesUpdated Jul 19, 2026Avg 30-Day Volume
306.92KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.17USDUpdated Jul 19, 2026Other Income / Expense
115.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 28.88×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 28.88Industry median: 5.64Industry P95: 23.02Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.26B, above the global median of $1.15BNotable
Market cap (USD): 2,255,268,933Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zai Lab Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule